Agios, Celgene End Collaboration to Develop Cancer Treatment AG-881

Agios Pharmaceuticals said it agreed with Celgene to end a three-year-old collaboration to develop and commercialize treatments containing its most advanced clinical cancer candidate AG-881 (vorasidenib), an oral inhibitor of both the isocitrate dehydrogenase-1 (IDH1) and IDH2 proteins.Agios stated in a regulatory filing that it will obtain sole global rights to AG-881. In return, Agios agreed to pay Celgene low-single-digit royalties on worldwide net sales of products containing AG-881—as